title: Experience with roxithromycin in visceral leishmaniasis in north Bihar.
abstract: In search of an oral drug for Visceral Leishmaniasis, 54 cases of Kala-azar were treated with roxithromycin, an orally administrable drug at a dose of 300 mg twice daily for 21 days. Thirty-nine (86.7%) were responsive (cured), 11 (28.2%) relapsed. The results appeared equally or even more effective when compared to the sodium antimony gluconate in two recent trials in Kala-azar in almost same demographic pattern. A possible synergistic action of roxithromycin and SAG was explored. Toxicities of SAG and roxithromycin are compared and discussed. Further controlled trials are needed before it can be widely used as first line drug for Indian Kala-azar in the present epidemic.
authors.affiliation: I.O.C. Hospital, Barauni, India.
authors.forename: S K
authors.initials: SK
authors.lastname: Lal
authors.forename: R
authors.initials: R
authors.lastname: Lal
authors.forename: S
authors.initials: S
authors.lastname: Lal
authors.forename: R
authors.initials: R
authors.lastname: Lal
authors.forename: B N
authors.initials: BN
authors.lastname: Lal
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D015575:Roxithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D015575:Roxithromycin